7月24日——Kenvue 公司披露，美国食品药品监督管理局（FDA）已正式批准泰诺（Tylenol）与萘普生（Naproxen）的复方制剂。这是市面上首款，也是唯一一款含有对乙酰氨基酚（650毫克）和萘普生钠（220毫克）的非处方（OTC）固定剂量组合产品。
不仅如此，FDA还授予了该新配方长达三年的市场独占权。这一举措，无疑为Kenvue在非处方止痛药领域的布局提供了坚实的护城河。
据Kenvue方面透露，这款名为“泰诺与萘普生”的新品很快将在美国各大主要零售商上架销售。从实验室到药房货架，这一进程正在加速推进。
对于消费者而言，这意味着一款全新的疼痛缓解选择即将触手可及。而对企业来说，这份独家授权则意味着在竞争激烈的OTC市场中，抢占了先机。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.